1. receive any clinical trial drug treatment for covid-2019 within 30 days before the screening assessment; 2. severe liver disease (e.g., child pugh score \>=c or ast\> 5 times of the upper limit); 3. patients with known severe renal insufficiency (estimated glomerular filtration rate \<=30ml / min/1.73 m2) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis; 4. co-infection of hiv, hepatitis b, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses; 5. female patients who have no sexual protection in the last 30 days prior to the screening assessment; 6. pregnant or lactating women or women using estrogen contraception; 7. patients who are planning to become pregnant during the study period or within 6 months after the end of the study period; 8. other conditions that the researchers consider not suitable for participating in this clinical trial.

1. receive any clinical trial drug treatment for covid-2019 within 30 days before the screening assessment; 2. severe liver disease (e.g., child pugh score \>=c or ast\> 5 times of the upper limit); 3. patients with known severe renal insufficiency (estimated glomerular filtration rate \<=30ml / min/1.73 m2) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis; 4. co-infection of hiv, hepatitis b, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses; 5. female patients who have no sexual protection in the last 30 days prior to the screening assessment; 6. pregnant or lactating women or women using estrogen contraception; 7. patients who are planning to become pregnant during the study period or within 6 months after the end of the study period; 8. other conditions that the researchers consider not suitable for participating in this clinical trial.

receive any clinical trial drug treatment for covid-2019 within 30 days before the screening assessment; severe liver disease (e.g., child pugh score >=c or ast> 5 times of the upper limit); patients with known severe renal insufficiency (estimated glomerular filtration rate <=30ml / min/1.73 m2) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis; co-infection of hiv, hepatitis b, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses; female patients who have no sexual protection in the last 30 days prior to the screening assessment; pregnant or lactating women or women using estrogen contraception; patients who are planning to become pregnant during the study period or within 6 months after the end of the study period; other conditions that the researchers consider not suitable for participating in this clinical trial.

receive any clinical trial drug treatment for covid-2019 within 30 days before the screening assessment; severe liver disease (e.g., child pugh score >=c or ast> 5 times of the upper limit); patients with known severe renal insufficiency (estimated glomerular filtration rate <=30ml / min/1.73 m2) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis; co-infection of hiv, hepatitis b, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses; female patients who have no sexual protection in the last 30 days prior to the screening assessment; pregnant or lactating women or women using estrogen contraception; patients who are planning to become pregnant during the study period or within 6 months after the end of the study period; other conditions that the researchers consider not suitable for participating in this clinical trial.

1. receive any clinical trial drug treatment for covid-2019 within 30 days before the screening assessment; 2. severe liver disease (e.g., child pugh score >=c or ast> 5 times of the upper limit); 3. patients with known severe renal insufficiency (estimated glomerular filtration rate <=30ml / min/1.73 m2) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis; 4. co-infection of hiv, hepatitis b, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses; 5. female patients who have no sexual protection in the last 30 days prior to the screening assessment; 6. pregnant or lactating women or women using estrogen contraception; 7. patients who are planning to become pregnant during the study period or within 6 months after the end of the study period; 8. other conditions that the researchers consider not suitable for participating in this clinical trial.

1. receive any clinical trial drug treatment for covid-2019 within 30 days before the screening assessment; 2. severe liver disease (e.g., child pugh score >=c or ast> 5 times of the upper limit); 3. patients with known severe renal insufficiency (estimated glomerular filtration rate <=30ml / min/1.73 m2) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis; 4. co-infection of hiv, hepatitis b, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses; 5. female patients who have no sexual protection in the last 30 days prior to the screening assessment; 6. pregnant or lactating women or women using estrogen contraception; 7. patients who are planning to become pregnant during the study period or within 6 months after the end of the study period; 8. other conditions that the researchers consider not suitable for participating in this clinical trial.